A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Colorectal Cancer Clinical Trial

Official title:

A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03953235
• Other study ID #: GO-005
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: July 18, 2019
• Est. completion date: March 10, 2023

Study information

• Verified date: September 2023
• Source: Gritstone bio, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. Based on the Phase 1 data, an updated vaccine candidate (SLATE-KRAS or version 2) was developed that removed 16 of the 20 mutations included in the original vaccine (version 1) and solely targets KRAS mutations.

Description:

Tumors harboring non-synonymous deoxyribonucleic acid (DNA) mutations can present peptides containing these mutations as non-self antigens in the context of HLA on the tumor cell surface. A fraction of mutated peptides result in neoantigens capable of generating T-cell responses that exclusively target tumor cells. Some of these tumor-specific neoantigens are known or expected to be common across a subset of patients and are called shared neoantigens. This study aims to target shared neoantigens using a heterologous prime/boost therapeutic vaccine approach (GRT-C903 first followed by GRT-R904) in combination with checkpoint blockade to stimulate an immune response. This study will explore the safety and early clinical activity of this neoantigen-based immunotherapy intended to induce T-cell responses specific for the shared neoantigens contained within the therapeutic vaccine. Phase 1 will test multiple doses and combinations with checkpoint blockade and Phase 2 will test for early signs of clinical activity using a vaccine regimen based on Phase 1 data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: March 10, 2023
• Est. primary completion date: March 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provide a signed and dated informed consent form prior to initiation of study-specific procedures.
• Patients with the indicated advanced or metastatic solid tumor as follows:

1. Microsatellite-stable colorectal cancer (MSS-CRC) who are currently receiving systemic treatment with a fluoropyrimidine and oxaliplatin and/or irinotecan that may include a VEGF or EGFR targeting therapy as their 1L therapy for metastatic disease OR who have experienced disease progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan that may include a VEGF or EGFR targeting therapy and have not received additional lines of systemic therapy in the metastatic setting.

2. Non-small cell lung cancer (NSCLC) who are currently receiving systemic treatment with an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-based chemotherapy OR who have experienced disease progression following treatment with an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-based chemotherapy (or anti-PD-(L)1 alone if patient refuses platinum-based chemotherapy), and have not received additional lines of systemic therapy in the metastatic setting.

3. Pancreatic ductal adenocarcinoma (PDA) who are currently receiving systemic cytotoxic chemotherapy as their 1L therapy for metastatic disease OR who have experienced disease progression on 1L systemic cytotoxic chemotherapy and have received no more than 1 prior line of therapy in the metastatic setting.

4. Any solid tumor histology where the patient has experienced disease progression with all available therapies known to confer clinical benefit

• Patient's tumor possesses one of the mutations listed below, and is determined to express a HLA allele for antigen presentation of the identified tumor mutation: VERSION 1.0 of the expression cassette: BRAF_G466V // CTNNB1_S37F // CTNNB1_S45F // CTNNB1_S45P // CTNNB1_T41A // ERBB2_Y772_A775dup // KRAS_G12C or NRAS_G12C // KRAS_G12D or NRAS_G12D // KRAS_G12V // KRAS_G13D // KRAS_Q61H or NRAS_Q61H // KRAS_Q61K or NRAS_Q61K // KRAS_Q61L or NRAS_Q61L // KRAS_Q61R or NRAS_Q61R // TP53_K132E // TP53_K132N // TP53_R213L // TP53_R249M // TP53_S127Y VERSION 2.0 of the expression cassette: KRAS_G12C or NRAS_G12C // KRAS_G12D or NRAS_G12D // KRAS_G12V or NRAS_G12V // KRAS_Q61H or NRAS_Q61H
• ECOG Performance Status 0 or 1
• Measurable disease according to RECIST v1.1
• Adequate organ function, as measured by laboratory values (criteria listed in protocol)

Exclusion Criteria:

• Tumors with genetic characteristics as follows:

1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1, RET, or TRK

2. Patients with known MSI-high disease based on institutional standard

• Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to a vaccination
• Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant bruising or bleeding following IM injections or blood draws
• History of allogenic/solid organ transplant
• Active, known, or suspected autoimmune disease
• Active tuberculosis or recent (<2 week) clinically significant infection, or evidence of active hepatitis B or hepatitis C
• Known history of positive test for human immunodeficiency (HIV) or known acquired immunodeficiency syndrome (AIDS) Complete inclusion and exclusion criteria are listed in the clinical study protocol.

Related Conditions & MeSH terms

• Colorectal Cancer
• Neoplasms
• Non-Small Cell Lung Cancer
• Pancreatic Cancer
• Shared Neoantigen-Positive Solid Tumors
• Solid Tumor

Intervention

Biological:
• GRT-C903
a shared neoantigen cancer vaccine prime
• GRT-R904
a shared neoantigen cancer vaccine boost
• nivolumab
anti-PD-1 monoclonal antibody
• ipilimumab
anti-CTLA-4 monoclonal antibody

Locations

Country	Name	City	State
United States	University of Chicago Medicine, Comprehensive Cancer Center	Chicago	Illinois
United States	The Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Virginia Cancer Specialists	Fairfax	Virginia
United States	MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	Tennessee Oncology	Nashville	Tennessee
United States	Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center	New York	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	Mayo Clinic Rochester	Rochester	Minnesota
United States	UCLA Medical Center	Santa Monica	California

Sponsors (2)

Lead Sponsor	Collaborator
Gritstone bio, Inc.	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs)		Initiation of study treatment through 100 days post-last dose (up to approximately 27 months)
Primary	Objective Response Rate (ORR) in Phase 2 using RECIST v1.1		Initiation of study treatment until disease progression (up to approximately 27 months)
Primary	Identify the recommended Phase 2 dose (RP2D) of GRT-C903 and GRT-R904		Up to approximately 6 months
Secondary	Measure the immune response to the neoantigens encoded by GRT-C903 and GRT-R904		Baseline to end of treatment (up to approximately 12 months)
Secondary	Objective Response Rate (ORR) in Phase 1 using RECIST v1.1		Initiation of study treatment until disease progression (up to approximately 27 months)
Secondary	Duration of response (DOR) using RECIST v1.1		Initiation of study treatment until disease progression (up to approximately 27 months)
Secondary	Clinical benefit rate (CBR) using RECIST v1.1		Initiation of study treatment until disease progression (up to approximately 27 months)
Secondary	Progression-free survival (PFS)		Up to approximately 4 years
Secondary	Overall survival (OS)		Up to approximately 4 years